|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-6-7
|
|
pubmed:abstractText |
In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate. No baseline participant characteristic consistently predicted increased bone density response to PTH(1-84), although women with larger changes in 1,25 dihydroxyvitamin D during therapy had larger increases in BMD.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0937-941X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
973-9
|
|
pubmed:dateRevised |
2010-5-10
|
|
pubmed:meshHeading |
pubmed-meshheading:17333451-Aged,
pubmed-meshheading:17333451-Aged, 80 and over,
pubmed-meshheading:17333451-Alendronate,
pubmed-meshheading:17333451-Biological Markers,
pubmed-meshheading:17333451-Bone Density,
pubmed-meshheading:17333451-Bone Density Conservation Agents,
pubmed-meshheading:17333451-Female,
pubmed-meshheading:17333451-Humans,
pubmed-meshheading:17333451-Lumbar Vertebrae,
pubmed-meshheading:17333451-Middle Aged,
pubmed-meshheading:17333451-Osteoporosis, Postmenopausal,
pubmed-meshheading:17333451-Parathyroid Hormone,
pubmed-meshheading:17333451-Vitamin D
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
|
|
pubmed:affiliation |
Department of Medicine/Endocrinology, University of California San Francisco, San Francisco, CA, USA. dsellmeyer@psg.ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Research Support, N.I.H., Extramural
|
